Regeneron Pharmaceuticals (REGN) to Post Quarterly Earnings on Thursday

Regeneron Pharmaceuticals (NASDAQ:REGN) is anticipated to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Regeneron Pharmaceuticals to post earnings of $10.21 per share and revenue of $3.8163 billion for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.22 EPS. On average, analysts expect Regeneron Pharmaceuticals to post $37 EPS for the current fiscal year and $42 EPS for the next fiscal year.

Regeneron Pharmaceuticals Price Performance

REGN opened at $667.17 on Tuesday. The company’s 50-day simple moving average is $636.53 and its two-hundred day simple moving average is $713.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The stock has a market capitalization of $70.53 billion, a P/E ratio of 16.26, a P/E/G ratio of 1.45 and a beta of 0.24. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $821.11.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Neutral Sentiment: Wall Street is focusing on Regeneron’s second-quarter 2026 results, with analysts evaluating expected revenue, earnings, and other operating metrics. The estimates could influence the stock ahead of the company’s report, but no new results were announced in these articles. Curious about Regeneron Q2 Performance
• Neutral Sentiment: An industry article highlighted emerging food-allergy therapies, including the continuing need for epinephrine as the standard treatment for severe reactions. The report does not announce a new Regeneron product or materially change the company’s outlook. Food Allergy Market on the Rise

Analysts Set New Price Targets

A number of research firms have recently issued reports on REGN. HSBC dropped their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Leerink Partners reissued a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. Finally, Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $787.88.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Dodge & Cox increased its holdings in Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after acquiring an additional 45,513 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares in the last quarter. Invesco Ltd. lifted its holdings in Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after purchasing an additional 408,649 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 38.0% during the fourth quarter. AQR Capital Management LLC now owns 995,710 shares of the biopharmaceutical company’s stock valued at $768,518,000 after purchasing an additional 274,356 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Regeneron Pharmaceuticals by 2.7% in the third quarter. Northern Trust Corp now owns 984,792 shares of the biopharmaceutical company’s stock worth $553,719,000 after purchasing an additional 26,223 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.